Phase 4 N=20 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Central Centrifugal Cicatricial Alopecia
Primary: Mean Change in Physician Global Assessment of Improvement (PGA-I) — 0.07 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
Central Centrifugal Cicatricial Alopecia
Primary: Shape of the Hairline Documented With Photographs — 8; 12; 2 Participants
Phase 2 N=51 Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Cicatricial Alopecia
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants
N/A N=30,901 Healthcare Disparities in Alopecia Areata
Alopecia Areata
Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants
Phase 2 N=149 Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24 — 9.3; 21.4; 47.4; 58.3…
N/A N=71 STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Alopecia, Androgenetic
Primary: Safety & Tolerability Assessment of SAE/AE — 5; 9; 12; 2 events
N/A N=6 Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
Fibrosing Alopecia · Frontal Fibrosing Alopecia · Central Centrifugal Cicatricial Alopecia
Primary: Total Area Hair Count (Frontal) — 86.8 Count per cm^2
N/A N=15 Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks
Stretch Marks · Striae Distensae · Cosmetic Appearance of Stretch Marks
Primary: Cosmetic Outcome- Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks — 3; 5 Participants
Phase 3 N=407 European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Alopecia Areata
Primary: Number of Participants With Adverse Events as a Measure of Safety — 308; 224 Participants
N/A N=45 Alefacept in Patients With Severe Scalp Alopecia Areata
Alopecia Areata
Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…
N/A N=30 Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Number of Patients With SALT50 — 1; 1 Participants
N/A N=30 The Effect of Platelet Rich Plasma on Non-scarring Alopecia
Androgenetic Alopecia · Alopecia
Primary: Number of Participants With Improvement — 8; 1 Participants
Phase 2 N=15 An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Alopecia Areata
Primary: Total Number of Participants With At Least 50% Hair Regrowth — 1 Participants
Phase 2 N=20 Trial of Topical Cidofovir for the Prevention of Hair Growth
Prevention of Hair Growth
Primary: Physician's Global Assessment (PGA) of Hair Density — 1; 0; 1 participants
Phase 3 N=706 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Alopecia Areata
Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24 — 0.8; 29.6; 41.5 percentage of participants — p=<0.0001
Phase 3 N=517 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Alopecia Areata
Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24 — 0.8; 33.0; 38.3 Percentage of participants — p=<0.0001
Phase 2 N=60 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale
Phase 3 N=153 Real World CCH Study in Adult Females With Cellulite
Edematous Fibrosclerotic Panniculopathy (EFP) · Cellulite
Primary: The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Posterolateral Thigh — 58 Participants
N/A N=31 Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
Multiple Myeloma
Primary: Change in Development of Hair Loss — 30; 0; 0; 4 Participants
Phase 3 N=718 PF-06651600 for the Treatment of Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 — 30.65; 22.31; 23.39; 14.29 Percentage of…
Phase 2 N=35 A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia
Primary: Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12. — -3.10…
Phase 2 N=317 A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose…
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
Phase 2 N=66 Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Alopecia Areata
Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 58.44; 51.96 percent change
Phase 2 N=57 Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
Alopecia Areata
Primary: Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 — 46.4; 18.0 percent change
Phase 3 N=219 Subject Preference for Scalp Psoriasis Treatment
Scalp Psoriasis
Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003
Phase 2 N=12 Valchlor in the Treatment of Lichen Planopilaris
Lichen Planopilaris
Primary: Change in Lichen Planopilaris Activity Index (LLPAI) — -42.9; -66.7 percentage of change from baseline — p=0.014
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 3 N=326 Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
Scalp Seborrheic Dermatitis
Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01
N/A N=7 Adipose-derived SVF for Treatment of Alopecia
Androgenetic Alopecia
Primary: Incidence of Treatment-emergent Adverse Events (Safety) — 0 adverse events